<a href='https://providers.clevelandclinic.org/provider/steven-nissen/4268279'>Steven Nissen, MD</a>, and <a href='https://providers.clevelandclinic.org/provider/luke-laffin/4268377'>Luke Laffin, MD</a>, discuss one-year follow-up data for CTX310, a CRISPR-Cas9 gene-editing therapy targeting ANGPTL3 to treat lipid disorders. They review the sustained reductions in LDL cholesterol and triglycerides, and the potential role of one-time gene-editing therapies in cardiovascular prevention and lipid management. <a href='https://consultqd.clevelandclinic.org/effects-of-crispr-cas9-gene-editing-for-dyslipidemia-endure-1-year'>Read the article</a>. <a href='https://consultqd.clevelandclinic.org/effects-of-crispr-cas9-gene-editing-for-dyslipidemia-endure-1-year'>https://consultqd.clevelandclinic.org/effects-of-crispr-cas9-gene-editing-for-dyslipidemia-endure-1-year</a>

Steven Nissen, MD, and Luke Laffin, MD, discuss one-year follow-up data for CTX310, a CRISPR-Cas9 gene-editing therapy targeting ANGPTL3 to treat lipid disorders. They review the sustained reductions in LDL cholesterol and triglycerides, and the potential role of one-time gene-editing therapies in cardiovascular prevention and lipid management.  Read the article. https://consultqd.clevelandclinic.org/effects-of-crispr-cas9-gene-editing-for-dyslipidemia-endure-1-year 

CTX310 and the Future of Gene Editing for Lipid Disorders

Description